Niraparib in the Treatment of Patients with Advanced PALB2 Mutated Tumors
The purpose of this study is to further evaluate the efficacy and safety of niraparib in patients with locally advanced or metastatic solid tumors and a pathogenic or likely pathogenic tumor PALB2 (tPALB2) mutation.
Solid Tumor|Breast Tumor|Colon Tumor, Malignant|Lung Tumor|Urologic Cancer|Pancreatic Cancer|Melanoma|Metastatic Cancer|Locally Advanced Solid Tumor|Esophageal Cancer|Endometrial Cancer|Head and Neck Cancer
DRUG: Niraparib
Overall Response Rate (ORR) - Independent Central Review (ICR), To evaluate overall response rate (ORR) as assessed by Independent Central Review (ICR) using RECIST v1.1, Up to 4 years
Duration of Response (DOR) - Independent Central Review (ICR), To evaluate duration of response (DOR) as assessed by ICR using RECIST v1.1, Up to 4 years|Progression-Free Survival (PFS) - Independent Central Review (ICR), To evaluate progression-free survival (PFS) as assessed by ICR using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), Up to 4 years|Overall Response Rate (ORR) - Investigator, To evaluate ORR as assessed by Investigator using RECIST v1.1, Up to 4 years|Duration of Response (DOR) - Investigator, To evaluate DOR as assessed by Investigator using RECIST v1.1, Up to 4 years|Progression-Free Survival (PFS) - Investigator, To evaluate PFS as assessed by Investigator using RECIST v1.1, Up to 4 years|Clinical Benefit Rate (CBR) - Investigator and ICR, To evaluate Clinical Benefit Rate (CBR) as assessed by ICR and Investigator, Up to 4 years|ORR with untreated measurable CNS lesions - Investigator, To evaluate intracranial ORR in participants with untreated measurable CNS lesions as assessed by Investigator using RECIST v1.1, Up to 4 years|ORR with untreated measurable CNS lesions - ICR, To evaluate intracranial ORR in participants with untreated measurable CNS lesions as assessed by ICR using RECIST v1.1, Up to 4 years|Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability), To evaluate safety and tolerability per the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE v5.0), Up to 4 years|Overall Survival (OS), To evaluate overall survival (OS), Up to 4 years
The purpose of this study is to further evaluate the efficacy and safety of niraparib in patients with locally advanced or metastatic solid tumors and a pathogenic or likely pathogenic tumor PALB2 (tPALB2) mutation.